Barclays initiates coverage on Novartis (NYSE: NVS) with a Underweight rating.Analyst Dr. Emmanuel Papadakis comments"Novartis is diversified, relatively low risk ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE